Back to homepage

Immunology

Targeting eosinophils: severe asthma and beyond

Authors: Marco Caminati MD, Francesco Menzella MD, Lucia Guidolin MD, Gianenrico Senna MD

This review summarizes the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action.

More

Guselkumab for the treatment of psoriasis – evidence to date

Authors: Miguel Nogueira MD, Tiago Torres MD, PhD

This review highlights the evidence available to date for the use of guselkumab for the treatment of psoriasis. The results of the recent ECLIPSE trial are addressed.

More

Novel therapeutic targets for allergic airway disease in children

Authors: Alessandro Giallongo MD, Giuseppe Fabio Parisi MD, Amelia Licari MD, Giulio Pulvirenti MD, Caterina Cuppari MD, Carmelo Salpietro MD, Gian Luigi Marseglia MD, Salvatore Leonardi MD

Keywords: allergic airway disease, allergic rhinitis, asthma, biologics, children, chronic rhinosinusitis, immunotherapy. Citation: Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Novel therapeutic targets for allergic airway disease in children. Drugs in

More

Brodalumab in psoriasis: evidence to date and clinical potential

Authors: Amy C Foulkes BMedSci (Hons), BMBS, MRCP (Derm), PhD, Richard B Warren BSc (Hons), MBChB (Hons), MRCP, PhD

This article reviews brodalumab’s place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis.

More

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Authors: Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

More